Modulation of microbiota as a target in the management of patients with irritable bowel syndrome

Irritable  bowel syndrome  (IBS) is one of the  most common  diseases  of the  digestive  tract. IBS negatively  affects  the  quality of life and work ability of patients. It is generally  accepted that  IBS is an important medical  and social problem  associated with high financial  costs  both  on the  part of the  patient  and the  public health  system. The pathophysiology of the  disease involves the participation of many factors (genetic, dietary, psychosocial, infectious) and the mechanisms of their implementation, including  disruption  of interaction along  the  functional  “gut-brain axis”, visceral  hypersensitivity,  changes  in motility, low-grade  inflammation, increased permeability of the epithelial intestinal barrier, modulation of microbiota, changes  in neurohumoral  regulation and  processes of central  processing  of peripheral stimuli. Research  shows  an important role  for gut microbiota  in the development of IBS. Modulation of the intestinal microbiota  through  diet, the use of pre- and probiotics  or fecal microbiota transplantation is considered as a promising target  for disease  therapy. A reduction  in the number of bacteria of the genus  Bifidobacterium is described  as a universal  change  in the microbiota  in IBS, regardless of the clinical course and severity of the disease  and the possibility of using different  strains of Bifidobacterium in treatment regimens  for the disease  is of particular  interest. This article  provides  a review of the literature on modern  approaches to prescribing  probiotics  for IBS. Using our own clinical observations as an example, we demonstrated the effectiveness and safety of prolonged administration of the probiotic strain Bifidobacterium longum 35624®  for up to 12 weeks.

1. Ivashkin VT, Maev IV, Shelygin YuA, Baranskaya EK, Belous SS, Belousova EA et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-74-95.

2. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.

3. Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med. 2017;129(8):872–888. https://doi.org/10.1080/00325481.2017.1383819.

4. Salem AE, Singh R, Ayoub YK, Khairy AM, Mullin GE. The gut microbiome and irritable bowel syndrome: State of art review. Arab J Gastroenterol. 2018;19(3):136–141. https://doi.org/10.1016/j.ajg.2018.02.008.

5. El-Salhy M, Patcharatrakul T, Gonlachanvit S. The role of diet in the pathophysiology and management of irritable bowel syndrome. Indian J Gastroenterol. 2021;40(2):111–119. https://doi.org/10.1007/s12664-020-01144-6.

6. Ghaffari P, Shoaie S, Nielsen LK. Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. J Transl Med. 2022;20(1):173. https://doi.org/10.1186/s12967-022-03365-z.

7. Wilmes L, Collins JM, O’Riordan KJ, O’Mahony SM, Cryan JF, Clarke G. Of bowels, brain and behavior: A role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(3):e14095. https://doi.org/10.1111/nmo.14095.

8. Osipenko MF, Livzan MA, Skalinskaya MI, Lyalyukova EA. Fecal calprotectin concentration in the differential diagnosis of bowel diseases. Terapevticheskii Arkhiv. 2015;87(2):30–33. (In Russ.) https://doi.org/10.17116/terarkh201587230-33.

9. Gaus OV, Livzan MA. Phenotypes of irritable bowel syndrome and strategies for patient-oriented curation of patient. Lechaschi Vrach. 2023;(7-8):36–44. (In Russ.) https://doi.org/10.51793/OS.2023.26.8.006.

10. Shrestha B, Patel D, Shah H, Hanna KS, Kaur H, Alazzeh MS et al. The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review. Cureus. 2022;14(8):e28064. https://doi.org/10.7759/cureus.28064.

11. Xiao L, Liu Q, Luo M, Xiong L. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. Front Cell Infect Microbiol. 2021;11:729346. https://doi.org/10.3389/fcimb.2021.729346.

12. Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev. 2017;279(1):70–89. https://doi.org/10.1111/imr.12567.

13. Sorbara MT, Pamer EG. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunol. 2019;12(1):1–9. https://doi.org/10.1038/s41385-018-0053-0.

14. Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017;74(16):2959–2977. https://doi.org/10.1007/s00018-017-2509-x.

15. Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S, Ro S. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. J Neurogastroenterol Motil. 2021;27(1):19–34. https://doi.org/10.5056/jnm20149.

16. Ojeda J, Ávila A, Vidal PM. Gut Microbiota Interaction with the Central Nervous System throughout Life. J Clin Med. 2021;10(6):1299. https://doi.org/10.3390/jcm10061299.

17. Stefano GB, Pilonis N, Ptacek R, Raboch J, Vnukova M, Kream RM. Gut, Microbiome, and Brain Regulatory Axis: Relevance to Neurodegenerative and Psychiatric Disorders. Cell Mol Neurobiol. 2018;38(6):1197–1206. https://doi.org/10.1007/s10571-018-0589-2.

18. Israelyan N, Margolis KG. Reprint of: Serotonin as a link between the gutbrain-microbiome axis in autism spectrum disorders. Pharmacol Res. 2019;140:115–120. https://doi.org/10.1016/j.phrs.2018.12.023.

19. Gaus OV, Livzan MA, Gavrilenko DA. Post-infectious irritable bowel syndrome: renaissance time? Medical Alphabet. 2021;(35):23–28. (In Russ.) https://doi.org/10.33667/2078-5631-2021-35-23-28.

20. Tojo R, Suárez A, Clemente MG, de los Reyes-Gavilán CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–15176. https://doi.org/10.3748/wjg.v20.i41.15163.

21. Barandouzi ZA, Lee J, Maas K, Starkweather AR, Cong XS. Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components. J Pers Med. 2021;11(1):35. https://doi.org/10.3390/jpm11010035.

22. Zhan K, Zheng H, Li J, Wu H, Qin S, Luo L, Huang S. Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome. Biomed Res Int. 2020;2020:3828249. https://doi.org/10.1155/2020/3828249.

23. Mishima Y, Ishihara S. Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome. Int J Mol Sci. 2020;21(22):8664. https://doi.org/10.3390/ijms21228664.

24. Gaus OV, Livzan MA. Gut microbiota modulation as a leading factor in the pathogenesis of the IBS phenotypes. RMJ. 2023;(5):12–19. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Modulyaciya_mikrobioty_kishechnika_kak_veduschiy_faktor_patogeneza_formirovaniya_fenotipov_sindroma_razdraghennogo_kishechnika/?ysclid=lnlnulgaul929122915.

25. Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):28–35. https://doi.org/10.1097/MED.0000000000000523.

26. Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289–310. https://doi.org/10.1007/s12325-018-0673-5.

27. Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302. https://doi.org/10.1111/nmo.12315.

28. Mazzawi T. Gut Microbiota Manipulation in Irritable Bowel Syndrome. Microorganisms. 2022;10(7):1332. https://doi.org/10.3390/microorganisms10071332.

29. Sun JR, Kong CF, Qu XK, Deng C, Lou YN, Jia LQ. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26(2):66–77. https://doi.org/10.4103/sjg.SJG_384_19.

30. Goodoory VC, Khasawneh M, Black CJ, Quigley EMM, Moayyedi P, Ford AC. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5):1206–1218. https://doi.org/10.1053/j.gastro.2023.07.018

31. Bahaka D, Neut C, Khattabi A, Monget D, Gavini F. Phenotypic and genomic analyses of human strains belonging or related to Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium breve. Int J Syst Bacteriol. 1993;43(3):565–573. https://doi.org/10.1099/00207713-43-3-565.

32. Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28–38. https://doi.org/10.1111/jgh.13471.

33. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15(23):2887–2892. https://doi.org/10.3748/wjg.15.2887.

34. Bai T, Zhang L, Wang H, Qian W, Song J, Hou X. Fecal Microbiota Transplantation Is Effective in Relieving Visceral Hypersensitivity in a Postinfectious Model. Biomed Res Int. 2018;2018:3860743. https://doi.org/10.1155/2018/3860743.

35. Ait-Belgnaoui A, Payard I, Rolland C, Harkat C, Braniste V, Théodorou V, Tompkins TA. Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation. J Neurogastroenterol Motil. 2018;24(1):138–146. https://doi.org/10.5056/jnm16167.

36. Zhou C, Fang X, Xu J, Gao J, Zhang L, Zhao J et al. Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation. Gut Microbes. 2020;12(1):1782156. https://doi.org/10.1080/19490976.2020.1782156.

37. Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Front Immunol. 2020;11:2192. https://doi.org/10.3389/fimmu.2020.02192.

38. Guarner F, Sanders ME, Szajewska H, Cohen H, Eliakim R, Herrera C et al. Probiotics and prebiotics: World Gastroenterology Organisation Global Guidelines; 2023. 52 p. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pdf.

39. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551. https://doi.org/10.1053/j.gastro.2004.11.050.

40. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–1590. https://doi.org/10.1111/j.1572-0241.2006.00734.x.

41. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28(7):732–744. https://doi.org/10.3748/wjg.v28.i7.732.

42. Lenoir M, Wienke J, Fardao-Beyler F, Roese N. An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2023. https://doi.org/10.1007/s12602-023-10151-w.

43. Solovyeva OI, Nekrasova AS, Topalova IG, Ponomarenko VA, Tsurtsumiia DB, Ilyashevich IG. Long-term probiotic administration for irritable bowel syndrome: a legal need. Terapevticheskii Arkhiv. 2023;95(8):679–685. (In Russ.) https://doi.org/10.26442/00403660.2023.08.202378.

44. Ivashkin VT, Maev IV, Abdulganieva DI, Alekseenko SA, Gorelov AV, Zakharova IN et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):65–91. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-2-65-91.

45. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214–1240. https://doi.org/10.1136/gutjnl-2021-324598.

46. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915–922. https://doi.org/10.1038/ajg.2010.480.

47. Johannesson E, Ringström G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600–608. https://doi.org/10.3748/wjg.v21.i2.600.

48. Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neuro­ gastroenterol Motil. 2019;31(2):e13461. https://doi.org/10.1111/nmo.13461.

49. Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022;10(6):556–584. https://doi.org/10.1002/ueg2.12259.